Last reviewed · How we verify
Treatment F
Treatment F is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently FDA-approved. Also known as: simeprevir.
Treatment F is not a recognized pharmaceutical product identifier in standard drug databases.
At a glance
| Generic name | Treatment F |
|---|---|
| Also known as | simeprevir |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Without a brand name, generic name, or specific molecular target provided, this appears to be either a placeholder designation or an internal research code. Standard pharmaceutical nomenclature and regulatory databases do not contain a marketed drug identified solely as 'Treatment F' from Merck Sharp & Dohme LLC.
Approved indications
Common side effects
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment F CI brief — competitive landscape report
- Treatment F updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Treatment F
What is Treatment F?
How does Treatment F work?
Who makes Treatment F?
Is Treatment F also known as anything else?
What development phase is Treatment F in?
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Also known as: simeprevir